HER2-IN-7

发表于2024年11月15日由上海金畔生物科技有限公司

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

HER2-IN-7

HER2-IN-7 是一种有效的 HER2 抑制剂。ErbB 家族信号的失调调节增殖、侵袭、转移、血管生成和肿瘤细胞存活。HER2-IN-7 具有研究ErbBs (尤其是HER2) 相关疾病的潜力，包括癌症 (摘自专利 WO2019214634A1，化合物 23)。

HER2-IN-7 Chemical Structure

CAS No. : 2387574-01-6

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	HER2-IN-7 is a potent inhibitor of HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2), including cancer (extracted from patent WO2019214634A1, compound 23)^[1].
分子量	565.55
Formula	C₂₈H₂₆F₃N₇O₃
CAS 号	2387574-01-6
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Zhengtao LI, et al. Erbb receptor inhibitors. Patent WO2019214634A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HER2-IN-7

发表于2024年11月15日由上海金畔生物科技有限公司

HER2-IN-7

HER2-IN-7 Chemical Structure

CAS No. : 2387574-01-6

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	HER2-IN-7 is a potent inhibitor of HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2), including cancer (extracted from patent WO2019214634A1, compound 23)^[1].
分子量	565.55
Formula	C₂₈H₂₆F₃N₇O₃
CAS 号	2387574-01-6
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Zhengtao LI, et al. Erbb receptor inhibitors. Patent WO2019214634A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HER2-IN-7

发表于2024年11月15日由上海金畔生物科技有限公司

HER2-IN-7

HER2-IN-7 Chemical Structure

CAS No. : 2387574-01-6

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	HER2-IN-7 is a potent inhibitor of HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2), including cancer (extracted from patent WO2019214634A1, compound 23)^[1].
分子量	565.55
Formula	C₂₈H₂₆F₃N₇O₃
CAS 号	2387574-01-6
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Zhengtao LI, et al. Erbb receptor inhibitors. Patent WO2019214634A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HER2-IN-8

发表于2024年11月15日由上海金畔生物科技有限公司

HER2-IN-8

HER2-IN-8 是一种 HER-2 的抑制剂，可用于研究癌症和炎症相关疾病，详细信息请参考专利文献 WO2021179274A1 中的化合物 107。

HER2-IN-8 Chemical Structure

CAS No. : 2704630-49-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

HER2-IN-8 is a HER-2 inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation^[1].

IC₅₀ & Target^[1]

HER2

分子量

549.53

Formula

C₂₆H₂₅F₂N₉O₃

CAS 号

2704630-49-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Zhou D, et, al. ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS. WO2021179274A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HER2-IN-8

发表于2024年11月15日由上海金畔生物科技有限公司

HER2-IN-8

HER2-IN-8 是一种 HER-2 的抑制剂，可用于研究癌症和炎症相关疾病，详细信息请参考专利文献 WO2021179274A1 中的化合物 107。

HER2-IN-8 Chemical Structure

CAS No. : 2704630-49-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

HER2-IN-8 is a HER-2 inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation^[1].

IC₅₀ & Target^[1]

HER2

分子量

549.53

Formula

C₂₆H₂₅F₂N₉O₃

CAS 号

2704630-49-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Zhou D, et, al. ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS. WO2021179274A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HER2-IN-8

发表于2024年11月15日由上海金畔生物科技有限公司

HER2-IN-8

HER2-IN-8 是一种 HER-2 的抑制剂，可用于研究癌症和炎症相关疾病，详细信息请参考专利文献 WO2021179274A1 中的化合物 107。

HER2-IN-8 Chemical Structure

CAS No. : 2704630-49-7

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

HER2-IN-8 is a HER-2 inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation^[1].

IC₅₀ & Target^[1]

HER2

分子量

549.53

Formula

C₂₆H₂₅F₂N₉O₃

CAS 号

2704630-49-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Zhou D, et, al. ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS. WO2021179274A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Trastuzumab(Synonyms: 曲妥珠单抗; Anti-Human HER2, Humanized Antibody)

发表于2024年10月25日由上海金畔生物科技有限公司

Trastuzumab (Synonyms: 曲妥珠单抗; Anti-Human HER2, Humanized Antibody) 纯度: 99.80%

Trastuzumab 是一种人源化 IgG1 单克隆抗体，其以高亲和力与 HER2 选择性结合。Trastuzumab 可用于 HER2 阳性转移性乳腺癌和 HER2 阳性胃癌的研究。

Trastuzumab Chemical Structure

CAS No. : 180288-69-1

规格	价格	是否有货
1 mg	￥1600	In-stock
5 mg	￥5500	In-stock
25 mg		询价
50 mg		询价

* Please select Quantity before adding items.

生物活性

Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

IC₅₀ & Target^[1]

HER2

体外研究
(In Vitro)

Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets^[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity^[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone^[1]. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

145531.50

Formula

C₆₄₇₀H₁₀₀₁₂N₁₇₂₆O₂₀₁₃S₄₂

CAS 号

180288-69-1

中文名称

曲妥珠单抗；曲妥单抗；群司珠单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70.

[2]. Hudis CA, et al. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51.

[3]. Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72.

Cell Assay ^[3]	The effects of Trastuzumab and Trastuzumab-F(ab′)₂ on the growth of JIMT-1, SKBR-3, and BT-474 cells are evaluated using the AlamarBlue method. Exponentially growing cells are harvested and plated in single wells of a 96-well flat-bottomed tissue culture plate at defined densities, ranging from 4,500-8,000 cells per well depending on the cell line. After overnight culture, the regular medium is exchanged to medium containing 0, 1, 10, or 100 μg/mL Trastuzumab or Trastuzumab-F(ab′) ₂. Cell viability is tested after 72 h of treatment. Fluorescence is detected at an excitation of 544 nm, and emission is detected at 590 nm^[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Trastuzumab and Trastuzumab-F(ab′)₂ are given at a dose of 5 and 25 μg/g, respectively, by weekly i.p. injection. The five times greater amount of administered F(ab′)₂ is chosen based on the different half-lives of IgG and F(ab′) F(ab′)₂. Control mice are treated with weekly i.p. injection of 100 μL physiologic saline (saline). Animals are euthanized by CO₂ inhalation^[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. [2]. Hudis CA, et al. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. [3]. Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

TAS0728

发表于2024年10月11日由上海金畔生物科技有限公司

TAS0728 纯度: 99.15%

TAS0728 是一种有效、选择性、可口服、不可逆、共价结合的 HER2 抑制剂，与 HER2 的 C805 位点共价结合，抑制其活性，IC₅₀ 值为 13 nM。TAS0728 对 BMX，HER4，BLK，EGFR，JAK3，SLK，LOK 和人 HER2 的 IC₅₀ 值分别为 4.9，8.5，31，65，33，25，86 和 36 nM。TAS0728 同时可抑制 HER2，HER3 及其下游效应蛋白的磷酸化。具有抗肿瘤活性。

TAS0728 Chemical Structure

CAS No. : 2088323-16-2

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥3885	In-stock
5 mg	￥3500	In-stock
10 mg	￥5500	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

TAS0728 相关产品

•相关化合物库:

Covalent Screening Library Plus
Drug Repurposing Compound Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
JAK/STAT Compound Library
Kinase Inhibitor Library
Protein Tyrosine Kinase Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Drug Repurposing Compound Library
Covalent Screening Library
Differentiation Inducing Compound Library
Orally Active Compound Library
Anti-Hepatitis C Virus Compound Library
Anti-Breast Cancer Compound Library
Anti-Lung Cancer Compound Library
Anti-Pancreatic Cancer Compound Library
Angiogenesis Related Compound Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, binds to HER2 at C805, inhibits its kinase activity, with an IC₅₀ of 13 nM. TAS0728 shows IC₅₀s of 4.9, 8.5, 31, 65, 33, 25, 86 and 36 nM for BMX, HER4, BLK, EGFR, JAK3, SLK, LOK and human HER2, respectively. TAS0728 also inhibits the phosphorylation of HER2, HER3, and downstream effectors, shows no obvious effect on EGFR. Antitumor activity^[1].

IC₅₀ & Target^[1]

HER4

8.5 nM (IC₅₀)

HER2

13 nM (IC₅₀)

Human HER2

36 nM (IC₅₀)

EGFR

65 nM (IC₅₀)

BMX

4.9 nM (IC₅₀)

BLK

31 nM (IC₅₀)

JAK3

33 nM (IC₅₀)

SLK

25 nM (IC₅₀)

LOK

86 nM (IC₅₀)

Clinical Trial

分子量

504.58

Formula

C₂₆H₃₂N₈O₃

CAS 号

2088323-16-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL (247.73 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9818 mL	9.9092 mL	19.8185 mL
5 mM	0.3964 mL	1.9818 mL	3.9637 mL
10 mM	0.1982 mL	0.9909 mL	1.9818 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.12 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.12 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.12 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Irie H, et al. TAS0728, a covalent-binding, HER2-selective kinase inhibitor shows potent antitumor activity in preclinical models. Mol Cancer Ther. 2019 Feb 20.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

生物活性分子抑制剂TX1-85-1

发表于2024年4月6日由上海金畔生物科技有限公司

生物活性分子抑制剂特异性抑制剂激动剂化合物库重组蛋白 TX1-85-1 纯度: 98.07%

TX1-85-1 是一种不可逆的 Her3 (ErbB3) 抑制剂，IC₅₀ 值为 23 nM。TX1-85-1 是第一个选择性 Her3 配体，与位于 Her3 的 ATP 结合位点的 Cys721 形成共价键。TX1-85-1诱发 Her3 蛋白部分降解，并减弱 Her3 依赖性信号传导。

TX1-85-1 Chemical Structure

CAS No. : 1603845-32-4

规格	价格	是否有货
1 mg	￥1100	In-stock
5 mg	￥2600	In-stock
10 mg	￥4500	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

TX1-85-1 相关产品

•相关化合物库:

Bioactive Compound Library Plus

生物活性

TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC₅₀ of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling^[1].

IC₅₀ & Target^[1]

ErbB3

23 nM (IC₅₀)

体外研究
(In Vitro)

TX1-85-1 possesses an anti-proliferation EC₅₀s of 9.9, 11.5, and 16.9 μM for Ovcar8, HCC827 GR6, and PC9 GR4 cells, respectively^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

580.68

Formula

C₃₂H₃₆N₈O₃

CAS 号

1603845-32-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

DMSO : 3.85 mg/mL (6.63 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7221 mL	8.6106 mL	17.2212 mL
5 mM	0.3444 mL	1.7221 mL	3.4442 mL
10 mM	—	—	—

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 0.38 mg/mL (0.65 mM); Clear solution

此方案可获得 ≥ 0.38 mg/mL (0.65 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 3.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 0.38 mg/mL (0.65 mM); Clear solution

此方案可获得 ≥ 0.38 mg/mL (0.65 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 3.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Xie T, et al. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol. 2014 Dec;10(12):1006-12.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HER2/neu (654-662) GP2

发表于2024年3月17日由上海金畔生物科技有限公司

HER2/neu (654-662) GP2

HER2/neu (654-662) GP2 是一种由 9 个氨基酸残基组成的多肽，来源于人类表皮生长因子受体 2 HER2/nue (654-662)，可诱导 HLA-A2 限制性细胞毒性 T 淋巴细胞 (CTL) 对多种上皮肿瘤发生反应。

HER2/neu (654-662) GP2 Chemical Structure

CAS No. : 160790-21-6

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers^[1]^[2].
分子量	884.11
Formula	C₄₂H₇₇N₉O₁₁
CAS 号	160790-21-6
Sequence	Ile-Ile-Ser-Ala-Val-Val-Gly-Ile-Leu
Sequence Shortening	IISAVVGIL
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Sun Y, et al. Observing the temperature dependent transition of the GP2 peptide using terahertz spectroscopy. PLoS One. 2012;7(11):e50306. [2]. Tanaka Y, et al. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes. Int J Cancer. 2001 Nov;94(4):540-4.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

多肽定制E75, Her – 2/neu (369-377) 编码

发表于2024年3月17日由上海金畔生物科技有限公司

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称	E75, Her – 2/neu (369-377)
编码
别名	E75, Her – 2/neu (369-377)
纯度	80%，90%，95%，98%，99%
重量	1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写）	KIFGSLAFL
序列（三字母缩写）	Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu
基本描述
溶解度
分子量	995.24
化学式	C50H78N10O11
存储条件	Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents
Figures
Reference
C端
N端
化学桥

多肽定制HER2/neu (654-662) GP2 编码

发表于2024年2月18日由上海金畔生物科技有限公司

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称	HER2/neu (654-662) GP2
编码
别名	HER2/neu (654-662) GP2
纯度	80%，90%，95%，98%，99%
重量	1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写）	IISAVVGIL
序列（三字母缩写）	Ile-Ile-Ser-Ala-Val-Val-Gly-Ile-Leu
基本描述
溶解度
分子量	884.12
化学式	C42H77N9O11
存储条件	Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents
Figures
Reference
C端
N端
化学桥

多肽定制HER2/neu (869-877) 编码

发表于2024年2月18日由上海金畔生物科技有限公司

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称	HER2/neu (869-877)
编码
别名	HER2/neu (869-877)
纯度	80%，90%，95%，98%，99%
重量	1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写）	LLDIDETEY
序列（三字母缩写）	Leu-Leu-Asp-Ile-Asp-Glu-Thr-Glu-Tyr
基本描述
溶解度
分子量	1110.19
化学式	C49H75N9O20
存储条件	Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents
Figures
Reference
C端
N端
化学桥

PROTAC Her3-binding moiety 1

发表于2024年1月19日由上海金畔生物科技有限公司

PROTAC Her3-binding moiety 1

PROTAC HER3-binding moiety 1 (compound 1b) 是 Her3 蛋白的配体。

PROTAC Her3-binding moiety 1 Chemical Structure

CAS No. : 1603845-36-8

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC^[1].
分子量	431.45
Formula	C₂₂H₂₁N₇O₃
CAS 号	1603845-36-8
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Nathanael Gray, et al.Bifunctional molescules for her3 degradation and methods of use. WO2017117473A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PROTAC Her3-binding moiety 1

发表于2024年1月19日由上海金畔生物科技有限公司

PROTAC Her3-binding moiety 1

PROTAC HER3-binding moiety 1 (compound 1b) 是 Her3 蛋白的配体。

PROTAC Her3-binding moiety 1 Chemical Structure

CAS No. : 1603845-36-8

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC^[1].
分子量	431.45
Formula	C₂₂H₂₁N₇O₃
CAS 号	1603845-36-8
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Nathanael Gray, et al.Bifunctional molescules for her3 degradation and methods of use. WO2017117473A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PROTAC Her3-binding moiety 1

发表于2024年1月19日由上海金畔生物科技有限公司

PROTAC Her3-binding moiety 1

PROTAC HER3-binding moiety 1 (compound 1b) 是 Her3 蛋白的配体。

PROTAC Her3-binding moiety 1 Chemical Structure

CAS No. : 1603845-36-8

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC^[1].
分子量	431.45
Formula	C₂₂H₂₁N₇O₃
CAS 号	1603845-36-8
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Nathanael Gray, et al.Bifunctional molescules for her3 degradation and methods of use. WO2017117473A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

HER2-IN-6

发表于2024年1月9日由上海金畔生物科技有限公司

HER2-IN-6

HER2-IN-6 是一种有效的 HER2 抑制剂。HER2-IN-6 具有研究野生和/或突变 EGFR 和/或 HER2 激酶介导的肿瘤的潜力 (摘自专利 WO2021164697A1，化合物 11)。

HER2-IN-6 Chemical Structure

CAS No. : 2691891-38-8

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性	HER2-IN-6 is a potent inhibitor of HER2. HER2-IN-6 has the potential for the research of wild and/or mutant EGFR and/or HER2 kinase mediated tumor (extracted from patent WO2021164697A1, compound 11)^[1].
分子量	504.58
Formula	C₂₆H₃₂N₈O₃
CAS 号	2691891-38-8
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Yihan Wang, et al. Substituted amide derivative and composition thereof and use thereof. Patent WO2021164697A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

EGFR/HER2-IN-2

发表于2023年12月15日由上海金畔生物科技有限公司

EGFR/HER2-IN-2

EGFR/HER2-IN-2 (Compound ZINC35560729) 是一种 EGFR 和 HER2 双重抑制剂，对 EGFR 和 HER2 的 IC₅₀ 分别为 5.02 µM 和 0.83 µM。

EGFR/HER2-IN-2 Chemical Structure

CAS No. : 1215571-02-0

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual inhibitor of EGFR and HER2 with IC₅₀ values of 5.02 µM and 0.83 µM against EGFR and HER2, respectively^[1].

IC₅₀ & Target

EGFR

5.02 μM (IC₅₀)

HER2

0.83 μM (IC₅₀)

分子量

453.49

Formula

C₂₆H₂₃N₅O₃

CAS 号

1215571-02-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Sangande, et al. 2-substituted 4-aminoquinazoline derivatives as potential dual inhibitors of EGFR and HER2: an in silico and in vitro study. Medicinal Chemistry Research 31.5 (2022): 762-771.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

EGFR/HER2-IN-3

发表于2023年12月14日由上海金畔生物科技有限公司

EGFR/HER2-IN-3

EGFR/HER2-IN-3 (Compound ZINC21942954) 是一种 EGFR 和 HER2 双重抑制剂。

EGFR/HER2-IN-3 Chemical Structure

CAS No. : 1031620-09-3

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual inhibitor of EGFR and HER2^[1].

IC₅₀ & Target

EGFR

HER2

分子量

453.49

Formula

C₂₆H₂₃N₅O₃

CAS 号

1031620-09-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Sangande, et al. 2-substituted 4-aminoquinazoline derivatives as potential dual inhibitors of EGFR and HER2: an in silico and in vitro study. Medicinal Chemistry Research 31.5 (2022): 762-771.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

pan-HER-IN-2

发表于2023年12月4日由上海金畔生物科技有限公司

pan-HER-IN-2

pan-HER-IN-2 (Compound C6) 是一种可逆的、具有口服活性的广谱 HER 抑制剂。对 EGFR、HER4、EGFR^T790M/L858R 和 HER2 的 IC₅₀ 分别为 0.72、2.0、8.2 和 75.1 nM。pan-HER-IN-2 诱导细胞凋亡 (apoptosis)，表现出抗肿瘤活性。

pan-HER-IN-2 Chemical Structure

CAS No. : 1639040-95-1

规格		是否有货
100 mg		询价
250 mg		询价
500 mg		询价

* Please select Quantity before adding items.

生物活性

pan-HER-IN-2 (Compound C6) is a reversible, orally active pan-HER inhibitor with IC₅₀ values of 0.72, 2.0, 8.2 and 75.1 nM against EGFR, HER4, EGFR^T790M/L858R and HER2, respectively. pan-HER-IN-2 induces apoptosis and shows antitumor activities^[1].

IC₅₀ & Target

EGFR

0.72 nM (IC₅₀)

EGFR (L858R/T790M)

8.2 nM (IC₅₀)

HER2

75.1 nM (IC₅₀)

HER4

2.0 nM (IC₅₀)

分子量

444.71

Formula

C₁₉H₁₅BrClN₅O

CAS 号

1639040-95-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献

[1]. Tang Q, et al. Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors. Eur J Med Chem. 2022 Apr 5;233:114249.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

whatman (沃特曼)

英国沃特曼 Millipore PALL中国代理商金畔官网

标签归档：her

HER2-IN-7

HER2-IN-7

HER2-IN-7

HER2-IN-8

HER2-IN-8

HER2-IN-8

Trastuzumab(Synonyms: 曲妥珠单抗; Anti-Human HER2, Humanized Antibody)

TAS0728

TAS0728 相关产品

•相关化合物库:

生物活性分子抑制剂TX1-85-1

TX1-85-1 相关产品

•相关化合物库:

HER2/neu (654-662) GP2

多肽定制E75, Her – 2/neu (369-377) 编码

多肽定制HER2/neu (654-662) GP2 编码

多肽定制HER2/neu (869-877) 编码

PROTAC Her3-binding moiety 1

PROTAC Her3-binding moiety 1

PROTAC Her3-binding moiety 1

HER2-IN-6

EGFR/HER2-IN-2

EGFR/HER2-IN-3

pan-HER-IN-2